Acumen Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 11.31 million compared to USD 9.13 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.23 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.365 USD | -6.53% | -9.38% | -11.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.98% | 216M | |
+64.54% | 62.59B | |
-1.24% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.51% | 26.21B | |
-21.66% | 19.09B | |
+4.91% | 13.08B | |
+25.57% | 12.26B | |
+28.05% | 12.05B |
- Stock Market
- Equities
- ABOS Stock
- News Acumen Pharmaceuticals, Inc.
- Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023